Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

India's new central bank chief Sanjay Malhotra is likely to take a growth-supportive approach over the next few months, as he ...

Sukhdev Singh is accused of fraudulently receiving approximately Rs 12 crore in compensation in collusion with some ...